Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Interest Expenses (2016 - 2025)

Guided Therapeutics' Interest Expenses history spans 16 years, with the latest figure at $184000.0 for Q4 2025.

  • On a quarterly basis, Interest Expenses rose 37.31% to $184000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $617000.0, a 61.94% increase, with the full-year FY2025 number at $617000.0, up 61.94% from a year prior.
  • Interest Expenses hit $184000.0 in Q4 2025 for Guided Therapeutics, up from $129000.0 in the prior quarter.
  • Over the last five years, Interest Expenses for GTHP hit a ceiling of $594000.0 in Q3 2021 and a floor of $64000.0 in Q1 2024.
  • Historically, Interest Expenses has averaged $150400.0 across 5 years, with a median of $118500.0 in 2024.
  • Biggest five-year swings in Interest Expenses: plummeted 73.91% in 2022 and later soared 129.69% in 2025.
  • Tracing GTHP's Interest Expenses over 5 years: stood at $100000.0 in 2021, then decreased by 30.0% to $70000.0 in 2022, then rose by 2.86% to $72000.0 in 2023, then surged by 86.11% to $134000.0 in 2024, then surged by 37.31% to $184000.0 in 2025.
  • Business Quant data shows Interest Expenses for GTHP at $184000.0 in Q4 2025, $129000.0 in Q3 2025, and $157000.0 in Q2 2025.